Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amphotericin B · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Fluconazole | DRUG | - |
| Amphotericin B | DRUG | - |
Inclusion Criteria * HIV infection documented by antibody (ELISA on two occasions or ELISA with Western blot confirmation), p24 antigen testing, or recovery of HIV in culture. Prior Medication: Required: * Minimum total dose of 15 mg/kg of amphotericin B (either alone or in combination with fluc...
Amphotericin B is an investigational small molecule being studied for the treatment of mycoses, meningitis, and cryptococcal infections. It is in Phase 3 clinical development for these infectious disease indications.
Amphotericin B is being developed by Pfizer, Inc., which trades under the ticker symbol PFE on the New York Stock Exchange.
Amphotericin B is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA for the indications being studied.
Amphotericin B has been studied in two completed Phase 3 trials. NCT00001017 compared fluconazole and Amphotericin B in treating brain infections in AIDS patients with cryptococcal meningitis, enrolling 330 participants. NCT00002277 compared the two drugs in treating fungal infections in HIV patients.
No, Amphotericin B is not the same as fluconazole. They are different antifungal drugs that have been compared against each other in clinical trials for treating fungal infections, including cryptococcal meningitis.